RAMB - Julho 2016

88 / 99

Cabral HWS et al.
376 Rev Assoc Med Bras 2016; 62(4):368-376
4. Pinheiro MM, Eis SR. Epidemiologia de fraturas pela osteoporose no
Brasil: o que temos e o que precisamos. Arq Bras Endocrinol Metab. 2010;
54(2):164-70.
5. Brasil. Ministério da Saúde. Quedas de idosos. SUS gasta quase R$ 81 milhões
com fraturas em idosos em 2009. [cited 2014 Nov]. Available from: http://
$-81-milh%C3%B5es-com-
fraturas-em-idosos-em-2009-saiba-mais!/.
6. Costa-Paiva L, Horowitz AP, Santos AO, Fonsechi-Carvasan GA, Pinto-
Neto AM. Prevalência de osteoporose em mulheres na pós-menopausa e
associação com fatores clínicos e reprodutivos. Rev Bras Ginecol Obstet.
2003; 25(7):507-12.
7. Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR. Low-dose
zoledronate in osteopenic postmenopausal women: a randomized controlled
trial. J Clin Endocrinol Metab. 2012; 97(1)286-92.
8. Lee J, Vasikaran S. Current recommendations for laboratory testing and use
of bone turnover markers in management of osteoporosis. Ann Lab Med.
2012; 32(2):105-12.
9. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin
Chem. 1999; 45(8 Pt 2):1359-68.
10. Lenora J, Gerdhem P, Obrant KJ, Ivaska KK. Bone turnover markers are
correlated with quantitative ultrasound of the calcaneus: 5-year longitudinal
data. Osteoporos Int. 2009; 20(7):1225-32.
11. Heaney RP. Pathophysiology of osteoporosis. Endocrinol Metab Clin North
Am. 1998; 27(2):255-65.
12. Grey A, Bolland M, Wong S, Horne A, G Gamble, Reid IR. Low-dose
zoledronate in osteopenic postmenopausal women: a randomized controlled
trial. J Clin Endocrinol Metab. 2012; 97(1):286-92 .
13. Borges JLC, Freitas A, Bilezikian JP. Accelerated fracture healing with
teriparatide. Arq Bras Endocrinol Metab. 2013; 57(2):153-6.
14. Jakob F, Oertel H, Langdahl B, Ljunggren O, Barrett A, Karras D, et al. Effects
of teriparatide in postmenopausal women with osteoporosis pre-treated
with bisphosphonates: 36-month results from the European Forsteo
Observational Study. Eur J Endocrinol. 2012; 166(1):87-97.
15. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, et
al.; IOF-IFCC Bone Marker Standards Working Group. Markers of bone
turnover for the prediction of fracture risk and monitoring of osteoporosis
treatment: a need for international reference standards. Osteoporos Int.
2011; 22(2):391-420.
16. Vasikaran SD, Cooper C, Kanis JA. Recommendations for bone marker
standards in osteoporosis: what, why and where to now? Ann Clin Biochem.
2011; 48(Pt2):91-2.
17. Vieira JGH. Diagnóstico laboratorial e monitoramento das doenças
osteometabólicas. J Bras Patol Med Lab. 2007; 43(2):75-82.
18. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis
Res Ther. 2007; 9(Suppl 1):S1.
19. Kuno R, Roquetti MH, Gouveia N. [Concepts and determination of reference
values for human biomonitoring of environmental contaminants]. Rev
Panam Salud Publica. 2010; 27(1):74-9.
20. Vasikaran SD, Glendenning P, Morris HA. The role of biochemical markers
of bone turnover in osteoporosis management in clinical practice. Clin
Biochem Rev. 2006; 27(3):119-21.
21. Kerschan-Schindl K, Mikosch P, Obermayer-Pietsch B, Gasser RW, Dimai
HP, Fahrleitner-Pammer A, et al. Current controversies in clinical management
of postmenopausal osteoporosis. Exp Clin Endocrinol Diabetes. 2014;
122(8):437-44.
22. Schafer AL, Vittinghoff E, Ramachandran R, Mahmoudi N, Bauer DC.
Laboratory reproducibility of biochemical markers of bone turnover in
clinical practice. Osteoporos Int. 2010; 21(3):439-45.
23. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new
biochemical markers of bone turnover in late postmenopausal osteoporotic
women in response to alendronate treatment. J Clin Endocrinol Metab.
1994; 79(6):1693-700.
24. Vasikaran SD, Cooper C, Kanis, JA. Recommendations for bone marker
standards in osteoporosis: what, why and where to now? Ann Clin Biochem.
2011; 48(Pt 2):91-2.
25. Chesnut CH 3rd, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson
CC Jr, et al. Hormone replacement therapy in postmenopausal women:
urinary n-telopeptide of type I collagen monitors therapeutic effect and
predicts response of bone mineral density. Am J Med. 1997; 102(1):29-37.
26. Romero Barco CM, Manrique Arija S, Rodríguez Pérez M. Biochemical
markers in osteoporosis: usefulness in clinical practice. Reumatol Clin. 2012;
8(3):149-52.